Xiangdong Liu

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish et al. · Blood · 2010 · 559 citations · Full text

Medicine, Immunology, Oncology +14

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR

Ulrike Litzenburger, Christiane A. Opitz, Felix Sahm et al. · Oncotarget · 2014 · 313 citations · Full text

Life Sciences, Immunology, Oncology +9

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

Eddy W. Yue, Richard Sparks, Padmaja Polam et al. · ACS Medicinal Chemistry Letters · 2017 · 296 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +8

Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model

Eddy W. Yue, Brent Douty, Brian Wayland et al. · Journal of Medicinal Chemistry · 2009 · 217 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Rebecca Kristeleit, Vadim Shirinkin, Fatima El-Khouly et al. · Gynecologic Oncology · 2017 · 101 citations · Full text

Medicine, Oncology, Pharmacology +15